As Fava & Balaise say, the trial wasn't futile as it has confirmed that:-
Withdrawal symptoms and syndromes may occur during and despite slow tapering, do not magically vanish after a couple of weeks from discontinuation and may persist for a long time, leading to postwithdrawal syndromes.As they also say:-
.. discontinuation that is performed without medical consultation and adequate psychotherapeutic support entails substantial risks for the patient and is often bound to fail
Fava and Balaise tend to emphasise their model of oppositional tolerance, which I have said before does not convince me (see previous post). Personally I have tended to argue for the importance of psychological dependence (eg. see previous post). This does get me into trouble with the 'prescribed harm' patient community, but despite what they may think, I am not minimising their problems, which mainstream psychiatry does (eg. see previous post). As Fava & Balaise conclude:-
The time has come to initiate research on withdrawal phenomena related to AD [antidepressants], and to redefine the use and indications of these medications
1 comment:
Should anybody wish to contribute towards research which will be genuinely focused on those many who already have been harmed by ADs and have had experience of withdrawal there is an opportunity to make it happen without waiting for all the evasions and delays the usual organisations colleges will put up. See Risk.org blog and Rxisk prize. There is no urgency by any psychiatric institution just more talk while thousands more individuals are harmed often for life. susanne
Post a Comment